Search Results

Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.

• Authors : Buggisch, Peter; Wursthorn, Karsten; Stoehr, Albrecht

Subjects: HEPATITIS C treatment; HEPATITIS C; HEPATITIS C virusGERMANY; EUROPEEUROPEAN Union

• Source: PLoS ONE; 4/4/2019, Vol. 14 Issue 4, p1-10, 10p

Record details

Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older.

• Authors : Foster, Graham R.; Asselah, Tarik; Kopecky-Bromberg, Sarah

Subjects: HEPATITIS C treatment; THERAPEUTIC use of protease inhibitors; HEALTH of older people

• Source: PLoS ONE; 1/2/2019, Vol. 14 Issue 01, p1-13, 13p

Record details

Pharmacists performing hepatitis C antibody point-of-care screening in a community pharmacy: A pilot project.

• Authors : Dong, Betty J.; Lopez, Maria; Cocohoba, Jennifer

Subjects: HEPATITIS C treatment; MEDICATION errors; DRUG prescription lawsUNITED States; CALIFORNIA

• Source: Journal of the American Pharmacists Association: JAPhA; Jul/Aug2017, Vol. 57 Issue 4, p510-515.e2, 6p

Record details

Commentary on Senn et al. (2009): Primary care is the place to manage hepatitis C in opiate-dependent patients.

• Authors : ROBERTSON, J. ROY (AUTHOR)

Subjects: PRIMARY care; MEDICAL screening; HEALTH services administration

• Source: Addiction. Dec2009, Vol. 104 Issue 12, p2039-2040. 2p.

Record details

HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment.

• Authors : Sarrazin, Christoph; Manns, Michael; Calleja, Jose Luis

Subjects: RIBAVIRIN; HEPATITIS C treatment; GENOTYPES

• Source: PLoS ONE; 12/28/2016, Vol. 11 Issue 12, p1-10, 10p

Record details

Treatment Selection Choices Should Not Be Based on Benefits or Costs Alone: A Head-to-Head Randomized Controlled Trial of Antiviral Drugs for Hepatitis C.

• Authors : Davitkov, Perica; Chandar, Apoorva Krishna; Hirsch, Amy

Subjects: HEPATITIS C treatment; ANTIVIRAL agents; MEDICAL care costs

• Source: PLoS ONE; 10/14/2016, Vol. 11 Issue 10, p1-11, 11p

Record details

Treatment of hepatitis C virus infection: Updated Swedish Consensus recommendations.

• Authors : Lagging, Martin (AUTHOR); Wejstål, Rune (AUTHOR); Uhnoo, Ingrid (AUTHOR)

Subjects: VIRUS diseases; CLINICAL medicine; HEPATITIS C treatment

• Source: Scandinavian Journal of Infectious Diseases. 2009, Vol. 41 Issue 6/7, p389-402. 14p. 8 Charts.

Record details

Individualized Treatment of Genotype 1 Naïve Patients: An Italian Multicenter Field Practice Experience.

• Authors : Mangia, Alessandra; Cenderello, Giovanni; Orlandini, Alessandra

Subjects: GENOTYPES; TELAPREVIR; BOCEPREVIREUROPE

• Source: PLoS ONE; Oct2014, Vol. 9 Issue 10, p1-8, 8p

Record details

"That was quick, simple, and easy": Patient perceptions of acceptability of point-of-care hepatitis C RNA testing at a reception prison.

• Authors : Lafferty, Lise^1,2 ; Cochrane, Amanda^2,3; Sheehan, Yumi²

Subjects: *PRISONS; *HEPATITIS C treatment; *POINT-of-care testingAUSTRALIA

• Source: International Journal of Drug Policy. Jan2022, Vol. 99, pN.PAG-N.PAG. 1p.

Record details

Validation of interleukin 28B genotyping assay for clinical use.

• Authors : Cervinski, Mark A.¹ ; Sam, Soya S.¹; Steinmetz, Heather B.¹

Subjects: *HEPATITIS C treatment; *INTERLEUKINS; *CLINICAL medicine

• Source: Clinical Biochemistry. Apr2014, Vol. 47 Issue 6, p478-480. 3p.

Record details

Point-of-care Hepatitis C virus testing and linkage to treatment in an Australian inner-city emergency department.

• Authors : Hutton, J.^1,2 ; Doyle, J.^3,4,5; Zordan, R.^2,6

Subjects: *HEPATITIS C treatment; *POINT-of-care testing; *EMERGENCY medicineAUSTRALIA

• Source: International Journal of Drug Policy. Oct2019, Vol. 72, p84-90. 7p.

Record details

U.S. veterans’ experience with Rebetron in a nonstudy environment: success or failure?

• Authors : Morelli, Joseph¹; Kim, Christopher Y.²; Willner, Ira R.¹

Subjects: *HEPATITIS C treatment; *CLINICAL medicine

• Source: American Journal of Gastroenterology (Springer Nature). Sep2002, Vol. 97 Issue 9, p2379. 4p.

Record details

Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.

• Authors : Scott, Nick^1,2 ; Doyle, Joseph S.^1,3; Wilson, David P.¹

Subjects: *HEPATITIS C treatment; *ANTIVIRAL agents; *INTRAVENOUS drug abusersAUSTRALIAWORLD Health Organization

• Source: International Journal of Drug Policy. Sep2017, Vol. 47, p107-116. 10p.

Record details

Quest Diagnostics Launches Hepatitis C Virus Therapy Test Based on IL28B Gene Variants.

Subjects: DIAGNOSIS; NONINVASIVE diagnostic tests; INTERFERONSQUEST Diagnostics Inc.

• Source: Biomedical Market Newsletter; 5/5/2011, p763-765, 3p

Record details

Highlights.

Subjects: CLINICAL medicine; HEPATITIS C treatment; COLON cancerUNITED States; CANADA

• Source: Clinical Pharmacology & Therapeutics; Feb2012, Vol. 91 Issue 2, p158-159, 2p

Record details

Optimum Duration of Treatment for Hepatitis C.

Subjects: *HEPATITIS C treatment; *HEPATITIS C virus; *RIBAVIRIN

• Source: Neurology Alert. Sep2007 Supplement, Vol. 26, p18-18. 1/5p.

Record details

Hepititis patient discouraged over treatment failure.

• Authors : Donohue, Paul G.

Subjects: THERAPEUTICS; HEPATITIS C treatment; HEART diseases

• Source: Adirondack Daily Enterprise. 10/20/2010, Vol. 117 Issue 248, p6-6. 1/5p.

Record details

Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy.

• Authors : Ogawa, Eiichi¹; Furusyo, Norihiro¹; Nakamuta, Makoto²

Subjects: *ANEMIA diagnosis; *CLINICAL medicine; *HEPATITIS C treatment

• Source: Journal of Hepatology. Oct2013, Vol. 59 Issue 4, p667-674. 8p.

Record details